Somewhat Positive News Coverage Somewhat Unlikely to Impact Tetraphase Pharmaceuticals (NASDAQ:TTPH) Share Price

Headlines about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.3448573696938 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news headlines that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

TTPH stock opened at $3.05 on Wednesday. Tetraphase Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $8.75. The company has a market cap of $158.91, a P/E ratio of -1.16 and a beta of 2.61.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. The firm had revenue of $2.53 million for the quarter, compared to analyst estimates of $2.26 million. research analysts predict that Tetraphase Pharmaceuticals will post -1.58 earnings per share for the current year.

Several equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, February 6th. BMO Capital Markets cut Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research note on Wednesday, February 14th. Stifel Nicolaus dropped their price target on Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, February 14th. WBB Securities assumed coverage on Tetraphase Pharmaceuticals in a research report on Thursday, February 22nd. They set a “speculative buy” rating and a $6.00 price target on the stock. Finally, SunTrust Banks reissued a “buy” rating and set a $10.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.22.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at $54,425. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Tetraphase Pharmaceuticals (NASDAQ:TTPH) Share Price” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Insider Buying and Selling by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply